QUSVM
ELEV

Qiming U.S. Ventures Management’s Elevation Oncology ELEV Stock Holding History

Qiming U.S. Ventures Management’s Portfolio ELEV Stock Details ELEV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,370,142
Closed -$1.27M – 7
2023
Q4 		$1.27M Hold
2,370,142
– – 1.17% 7
2023
Q3 		$1.57M Hold
2,370,142
– – 2.09% 6
2023
Q2 		$3.6M Hold
2,370,142
– – 3.79% 6
2023
Q1 		$4.5M Hold
2,370,142
– – 5.45% 6
2022
Q4 		$2.25M Hold
2,370,142
– – 2.98% 7
2022
Q3 		$2.68M Hold
2,370,142
– – 3.89% 7
2022
Q2 		$3.32M Hold
2,370,142
– – 4.61% 7
2022
Q1 		$5.97M Hold
2,370,142
– – 5.61% 6
2021
Q4 		$14.3M Buy
+2,370,142
New +$16.4M 6.57% 5

Other funds holding ELEV

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Qiming U.S. Ventures Management's ELEV Position: Q1 2024 in Review

Qiming U.S. Ventures Management sold out of Elevation Oncology (ELEV) in Q1 2024, closing a stake of 2,370,142 shares — an estimated $1.27M sold.

Qiming U.S. Ventures Management first reported a position in ELEV in Q4 2021 and held it in 9 quarters. The position peaked at $14.3M in Q4 2021. 63 funds tracked by Wall St. Rank hold ELEV as of Q1 2024.

  • Qiming U.S. Ventures Management reported no remaining Elevation Oncology position as of Q1 2024 after selling out during the quarter.
  • Qiming U.S. Ventures Management sold 2,370,142 Elevation Oncology shares in Q1 2024, an estimated $1.27M.
  • Qiming U.S. Ventures Management first reported a position in Elevation Oncology in Q4 2021 and held it in 9 quarters.
  • Qiming U.S. Ventures Management's Elevation Oncology position peaked at $14.3M in Q4 2021.
  • 63 funds tracked by Wall St. Rank held Elevation Oncology as of Q1 2024.

Based on Qiming U.S. Ventures Management's 13F filing for Q1 2024, filed 14 May 2024.